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ABSTRACT
Introduction: Vandetanib has recently
demonstrated clinically meaningful benefits in
patients with unresectable, locally advanced or
metastatic medullary thyroid cancer (MTC).
Given the potential for long-term vandetanib
therapy in this setting, in addition to treatment
for disease-related symptoms, effective
management of related adverse events (AEs) is
vital to ensure patient compliance and
maximize clinical benefit with vandetanib
therapy.
Methods: This expert meeting-based review
aims to summarize published data on AEs
associated with vandetanib therapy and to
provide clinicians with specific practical
guidance on education, monitoring, and
management of toxicities induced in patients
treated with vandetanib in advanced and
metastatic MTC. The content of this review is
based on the expert discussions from a
multidisciplinary meeting held in October 2012.
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Results: Characteristics, frequency, and risk data
are outlined for a number of dermatological,
cardiovascular, gastrointestinal, and general AEs
related to vandetanib treatment. Preventive
strategies, practical treatment suggestions, and
points for clinical consideration are provided.
Conclusions: Good patient and team
communication is necessary for the
prevention, early detection, and management
of AEs of vandetanib. Physicians, nurses, and
other healthcare providers play a critical role in
providing AE management and patient support
to optimize outcomes with vandetanib in MTC.
Keywords: Adverse effects; Antineoplastic
agents/adverse effects; Cardiovascular;
Dermatology; Medullary thyroid cancer;
Medullary thyroid carcinoma; Patient safety;
Piperidines/therapeutic use; Protein kinase
inhibitors; Thyroid neoplasms/drug therapy;
Vandetanib
INTRODUCTION
Medullary thyroid carcinoma (MTC) arises from
calcitonin-secreting parafollicular cells of the
thyroid and accounts for less than 5% of all
thyroid cancers [1]. The 10-year survival rate for
patients with MTC is 96% if the disease is
treated while the tumor is confined to the
thyroid gland [2]. Distant metastases are
observed at presentation in 7–23% of patients
[1]. Of these, about 40% will die of the disease
within 2 years after the diagnosis of distant
metastases, whereas about 40% are still alive
after 10 years [2]. Altogether, distant metastases
are the leading cause of MTC-related death [1].
Until recently, therapeutic options for rare
cases of advanced, unresectable MTC have been
limited, but advances in the understanding of
the pathogenesis of MTC have led to the
development of targeted therapies for this
disease. Vandetanib is a once-daily oral tyrosine
kinase inhibitor (TKI) that selectively targets the
rearranged during transfection (RET) proto-
oncogene, vascular endothelial growth factor
receptor (VEGFR), and epidermal growth factor
receptor (EGFR) [3, 4]. Vandetanib (Caprelsa,
ZD6474; AstraZeneca, Macclesfield, UK) is the
first drug approved for the treatment of adult
patients with unresectable, locally advanced, or
metastatic disease in the United States and
Europe [5, 6]. Long-term treatment with
vandetanib has demonstrated a statistically
significant longer median progression-free
survival versus placebo (30.5 vs 19.3 months;
p = 0.001) in this setting [7]. This underscores the
need to anticipate and effectively manage
therapy-related adverse events (AEs) that will,
in turn, promote patient compliance and,
therefore, maximize clinical benefit.
Based on clinical studies, the most common
AEs reported for vandetanib in MTC are diarrhea,
rash and folliculitis, nausea, corrected QT
interval (QTc) prolongation, hypertension, and
fatigue [7–9]. Endocrine effects evidenced by
increased thyroxine, calcium, and vitamin D
analog requirements have also been noted [10].
The majority of AEs are manageable according to
standard clinical practice alone or in
combination with vandetanib dose reductions,
and data indicate that severe AEs are not
sustained over the course of treatment [11].
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In the Phase III Zactima Efficacy in Thyroid
Cancer Assessment (ZETA) study, patients with
locally advanced or metastatic MTC were
randomized 2:1 to vandetanib 300 mg/day
(n = 231) or placebo (n = 100) [7]. Vandetanib
treatment led to a significant increase in the
primary endpoint of PFS [hazard ratio 0.46, 95%
confidence interval (CI) 0.31–0.69, p\0.001,
median follow-up 24 months] versus placebo
[7]. The median PFS was 19.3 months in the
placebo group, compared with a predicted
median PFS of 30.5 months for vandetanib [7].
Vandetanib also demonstrated significantly high
rates of objective response (45% versus 13% for
placebo; p\0.001), disease control (87% versus
71%; p = 0.001), and calcitonin biochemical
response (69% versus 3%; p\0.001) [7].
Furthermore, vandetanib was also active in
patients with sporadic disease and no detectable
RET mutations [7], suggesting that the presence
of a RET mutation is not a prerequisite for
patients to benefit from treatment [11].
Diarrhea, hypertension, prolongation of the
QTc, and fatigue were the most commonly
reported (incidence [5%) treatment-emergent
grade 3? AEs in the ZETA trial [7]. Additionally,
patients required an increase in thyroid hormone
replacement (vandetanib, 49.3% vs placebo,
17.2%). Nearly all patients experienced at least
one AE and 55% experienced a grade 3 or higher
AE [11]. Most AEs occurred 3–6 months after
treatment initiation [11]. Despite the frequency
of dose reductions [35% (81/231)] needed with
vandetanib, only 12% (28/231) of patients
discontinued treatment due to AEs [7].
Rash is the most frequently reported
dermatologic AE in vandetanib treatment,
occurring in more than 45% of vandetanib-
treated patients with MTC in the ZETA trial and
is second only to diarrhea [7]. Gastrointestinal
(GI) AEs included diarrhea (56%), nausea (33%;
11% grade 3?), decreased appetite (21%),
vomiting (14%), and abdominal pain (14%)
[7]. Fatigue and asthenia were reported by 24%
and 14% of vandetanib-treated patients in
ZETA, respectively.
QTc prolongation [500 ms (any grade) was
reported by 14% of vandetanib-treated patients
in ZETA versus 1% of those receiving placebo
[7]. No cases of Torsades de Pointes (TdP) were
reported [7], although two patients in a wider
drug-safety database had QTc intervals[550 ms
(one due to sepsis and one due to heart failure)
[6]. In a systematic review and meta-analysis
involving patients with a range of tumors
(n = 2,188), the overall incidence of all-grade
and high-grade QTc interval prolongation with
vandetanib 300 mg once-daily was 16.4% (95%
CI 8.1–30.4%) and 3.7% (95% CI 1.7–7.8%),
respectively, among patients with non-thyroid
cancer, and 18.0% (95% CI 10.7–28.6%) and
12.0% (95% CI 4.5–28.0%), respectively, among
patients with thyroid cancer [12]. Treatment
discontinuations due to QTc prolongation
(0.9%) and hypertension (0.9%) have been
reported [13].
In this review, we aim to summarize data in
the literature on AEs associated with vandetanib
therapy and provide community healthcare
providers with specific practical guidance on
patient education, monitoring, and
management of patients taking vandetanib for
MTC.
DISCUSSION
The Need for Optimal Management
of Vandetanib Therapy in MTC
As the majority of patients who respond to
vandetanib are likely to receive this TKI for
extended periods of time, all care providers,
including community healthcare physicians
Adv Ther (2013) 30:945–966 947
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and nurses, need to have a good understanding of
the drug’s safety profile and its potential impact
on quality of life and compliance with the drug.
Prior to initiating therapy, a review of past
medical history, current comorbidities, and
medications should be conducted, with an
emphasis on the potential interactions and
effects on vandetanib-related AEs. There is
controversy in the literature regarding the
optimal time to start tumor treatment in
patients with advanced MTC [1]. The size and
number of tumor foci, and the rate of change of
tumor volume during watchful waiting, may
help identify the optimal time to commence
treatment with vandetanib [6]. The rate of
change in serum levels of calcitonin and/or
carcinoembryonic antigen may also be taken
into account but should not be considered in
isolation. Table 1 shows a pragmatic consensus
of when to start systemic treatment in patients
with advanced MTC.
Vandetanib is typically given initially in
MTC as a once-daily 300 mg capsule taken
with or without food at about the same time
each day [5, 6], which may contribute to patient
acceptance and adherence. The prolonged half-
life of vandetanib (19 days) is a factor for
consideration in the management of any
potential AEs [6]; pharmacokinetic data for the
drug are published elsewhere [14]. Local
prescribing information should be consulted
for full details of dosage and administration
guidelines for vandetanib therapy.
Dose reduction may result in rapid AE
improvement, suggesting a direct toxic effect
of the agent. For grade 3 or 4 AEs, vandetanib is
discontinued until AEs resolve, after which
vandetanib therapy is resumed at a lower dose.
Efficacy is observed at doses lower than 300 mg/
day [15], and for long-term treatment finding a
dose that is well tolerated and allows a normal
quality of life may be the best way to ensure
patient compliance and avoid self-made
adjustments to medication.
Management of Dermatological AEs
Patients who receive vandetanib are at risk of
developing a rash (Fig. 1). In a systematic review
of trials involving 2,961 patients with a range of
tumors, including MTC, the incidence of all-
grade and high-grade rash/folliculitis associated
with vandetanib 300 mg was 46% (95% CI
40.6–51.8%) and 3.5% (95% CI 2.5–4.7%),
respectively [16]. The mechanism of the rash
has not been fully elucidated, but most
observed rashes, especially those presenting as
follicular pustules (Fig. 2), are probably due to
the anti-EGFR action of vandetanib, as anti-
EGFR agents are associated with acute and
subacute folliculitis [17]. It is thought that the
ability of vandetanib to block EGFR triggers
follicular hyperkeratosis, leading to follicle
obstruction and an inflammatory response
[18]. There is also a risk of superinfection of
these skin lesions.
Table 1 Decision matrix for initiating vandetanib
treatment in unresectable, locally advanced, or metastatic
medullary thyroid cancer
Progressiona Tumor burden
Small Large
\12–14 months Clinical judgment Yes
[12–14 months No Clinical judgmentb
Based on expert discussions; please refer to local
prescribing information and guidelines before prescribing
vandetanib
a Assessed via Response Evaluation Criteria in Solid
Tumors (RECIST)
b Considerations: vandetanib could be started as systemic
treatment, if there is a high standardized uptake value on
ﬂuorodeoxyglucose positron emission tomography scan; or
in the presence of symptoms (e.g. diarrhea, weight loss,
pain, dyspnea, tiredness); or if the tumor or metastases
located at a particular site are potentially harmful
948 Adv Ther (2013) 30:945–966
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Other cutaneous AEs observed with
vandetanib treatment include photosensitivity,
xerosis, finger clefts, paronychia, genital skin
reactions, subungual splinter hemorrhages, and
blue-gray macules [17]. Photosensitivity is
observed in all patients, even through glass
Fig. 1 Examples of rash seen with vandetanib treatment in patients with metastatic medullary thyroid cancer. a Rash on
hands and forearms; b photosensitivity rash on upper extremity and back
Fig. 2 Example of folliculitis in a patient treated with vandetanib. a Back; b front
Adv Ther (2013) 30:945–966 949
123
behind closed windows, and should be
prevented by protection against any sun
exposure. Blue-gray macules can be of variable
size and are usually located on the face, scalp, or
trunk (Fig. 3). They are very similar to the
pigmented macules observed on the skin and
cornea of patients receiving amiodarone [19],
which appear after several months of treatment
and usually disappear after treatment
interruption. Mucositis, erythrodysesthesia,
and hand-foot skin reactions are rare and
usually minor [17]. Rarely, serious skin
reactions such as Stevens–Johnson syndrome
and erythema multiforme have been reported
[20].
Cosmetically, dermatologic AEs can be
debilitating and may adversely affect patients’
quality of life [21], potentially resulting in
either interruption or discontinuation of
treatment. EGFR inhibitor-related skin toxicity
has been associated with a dose reduction in
60% of patients and treatment withdrawal in
32% [22]. Dermatologic AEs led to treatment
discontinuation much less frequently in
vandetanib-treated patients with MTC than
with other treatment options, with rash
(1.3%), eczema (0.4%), photosensitivity
reactions (0.4%), and pruritus (0.4%) [13].
Although frequent, dermatologic AEs are
generally manageable. Before starting
vandetanib treatment, it is critical to discuss
the potential development of skin reactions
with patients, initiate preventive measures, and
provide reassurance that these can usually be
managed effectively. An evaluation of mucosal
and skin surfaces is recommended whenever
patients attend clinic. Key management points
include strict photoprotection (e.g. use of a
broad-spectrum UVA/UVB sunscreen with a sun
protection factor of 30 or higher, avoidance of
any sun exposure by cloth protection) and
avoidance of products that dry the skin (e.g.
soaps, alcohol-based or perfumed products).
Early monitoring is essential to capture the
emergence of rash, which is generally treatable.
Collaboration with a dermatologist may be
needed in severe or complicated cases.
Questions to consider when dealing with a
rash are listed in Table 2. An extensive review
of commonly used topical and systemic
therapies to treat skin-related AEs induced by
vandetanib is shown in Table 3 [23–26].
Management of Cardiovascular AEs
Increased blood pressure and QTc prolongation
have been observed in patients taking
vandetanib. Based on a systematic review and
meta-analysis of 3,154 patients receiving
vandetanib, the incidences of all-grade and
high-grade hypertension were 24.2% (95% CI
18.1–30.2%) and 6.4% (95% CI 3.3–9.5%),
respectively [27]. Patients with MTC also had a
higher incidence of all-grade events than
patients with non-small cell lung cancer
(NSCLC) and non-MTC/NSCLC tumors
receiving vandetanib, with a relative risk of
1.36 (95% CI 1.05–1.76, p = 0.02) and 2.06
(95% CI 1.26–3.36, p = 0.004), respectively,
Fig. 3 Example of blue-gray macules on the forehead of a
patient treated with vandetanib. Arrows indicate small
spots on a greyish background
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Table 2 Topics that should be discussed with and carefully explained
to all patients before receiving vandetanib to avoid or reduce the
frequency of rash, diarrhea and other potential vandetanib-related
adverse events, and the level of disturbance to quality of life, through
awareness and early prevention by the patient
Rash
Are there any indicators of severe disease (e.g. systemic symptoms, eosinophilia, mucosal lesions, bullous lesions,
epidermal detachment)?
Is the rash related to vandetanib treatment? Consider alternatives (e.g. infection, other concomitant therapies)
Will treatment interruption be required? Prescribe local and/or systemic treatments
Diarrhea
Obtain a clear picture of the clinical course of diarrhea, including onset, duration, number of stools, and stool
composition
Perform an abdominal examination
Assess for signs of dehydration (e.g. dry mouth and skin, dizziness, weakness, decreased urine output, low blood pressure,
tachycardia)
Obtain medications and dietary proﬁle to identify diarrhea-causing agents and/or diarrhea-enhancing foods
Monitor closely for and correct serum electrolyte imbalances
For uncomplicated diarrhea, provide supportive advice
Stop all lactose-containing products, alcohol and high-osmolar supplements until diarrhea is controlled with
uncomplicated medications
Drink 8–10 glasses of water or clear liquids a day (e.g. broth)
Eat small frequent meals (e.g. bananas, rice, apple sauce, toast, plain pasta)
Treatment with loperamide (one pill after each stool) and codeine
For severe diarrhea, vandetanib should be stopped until diarrhea improves and then resumed at a reduced dose [6]
For persistent diarrhea after cessation of vandetanib, a stool workup for blood, infectious causes, and fecal leukocytes
should be performed if possible
Considerations for patient education
Provide clear and easily understandable guidance on what to do and who to contact if an adverse event occurs in
between visits to the treating clinic
Ask patients to contact the clinic if new side effects develop
Remind patients to contact the clinic if any new medications are prescribed by other healthcare providers
Teach patients how to measure blood pressure or ensure this is monitored regularly (e.g. at a general practice or by the
patients themselves)
Explain the necessity for frequent ECG and serum electrolyte monitoring
Ensure patients are aware of potential vandetanib-related adverse events (e.g. diarrhea, rash) and provide relevant advice
(e.g. dietary recommendations, skincare guidelines)
ECG electrocardiogram
Adv Ther (2013) 30:945–966 951
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probably due to longer treatment exposure at
higher doses [27].
Early detection and effective management of
hypertension according to current guidelines is
recommended, with close monitoring of blood
pressure during the first months of treatment.
Pre-existing hypertension should be managed
carefully before treatment initiation in line with
current guidelines, such as those from the fifth
joint task force of the European Society of
Cardiology, who define hypertension as blood
pressure C140/90 mmHg [28]. Angiotensin-
converting-enzyme (ACE) inhibitors are the
most commonly recommended anti-
hypertensive drugs for patients under
vandetanib treatment. Calcium antagonists
and beta-blockers are also helpful if
hypertension is not controlled with ACE
inhibitors alone. Blood pressure monitoring
1–3 times per month may be done by the
patients themselves to allow for close control of
hypertension without the need for specific
hospital visits.
The AE of most concern with vandetanib is
QTc prolongation, particularly in view of the
long terminal elimination half-life of the drug
Fig. 4 Schematic representation of normal electrocardio-
graphic trace. The QT interval is a measure of the time
between the start of the Q wave and the end of the T wave
on an ECG trace. Generally speaking, it represents electrical
depolarization and repolarization of the left and right
ventricles. A prolonged QT interval is a biomarker for
ventricular tachyarrhythmias such as Torsades de Pointes
and is a risk factor for sudden death. As the QT interval is
inﬂuenced by heart rate, the relative risk interval preceding
the QT interval is measured to correct for this. ECG
electrocardiogram
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[6]. The term ‘‘corrected’’ QT interval may be
misunderstood. It relates to the QT interval but
is adjusted for heart rate (Fig. 4). Definitions for
QTc interval prolongation vary in the literature,
and prolongation is characterized either in
absolute (e.g. [500 ms) or relative terms (e.g.
[30 ms change from baseline in QTc interval).
In general, an interval of above 480 ms is
considered prolonged.
Accurate measurement of the QTc interval is
best performed manually, rather than relying
on automatic measurements of standard ECG
machines, to guide treatment with QTc-
prolonging drugs [29]. Correction formulae
such as Bazett’s square root formula
(QTc = QT/RR1/2) are frequently used but are
often inaccurate at the extremes of
physiological heart rate [29]. Use of a QT
nomogram, which consists of a plot of QT
versus heart rate, is an alternative approach.
A QT interval–heart rate pair that plots above an
‘‘at-risk’’ line indicates that the patient is at risk
of TdP (Fig. 5) [30].
QTc prolongation above 450 ms is associated
with a risk of ventricular arrhythmias (e.g. TdP,
syncope, and sudden death), and the risk rises
with increasing durations of prolongation. First
QT prolongations occur most often in the first
3 months of treatment with vandetanib [6].
It is recommended that vandetanib should
be withheld if the QTc interval is longer than
500 ms until it returns to 450 ms, upon which a
reduced dose can be resumed [5]. A baseline
ECG with QTc measurement must be recorded
prior to initiation of vandetanib, and
vandetanib should not be given to patients
with a baseline QTc [450 ms (value may vary
depending on local product information).
During vandetanib treatment, mean
prolongation of QTc is 30 ms. Monitoring of
the QTc should be performed at least once every
month for the first 3 months on the drug.
Vandetanib therapy should be withheld and
the patient referred to a cardiologist as soon as
any new abnormality following the start of
vandetanib treatment is detected. Depending
Fig. 5 QTc interval nomogram for determining ‘at risk’
QTc–heart rate pairs from a single 12-lead ECG [30].
Reproduced with permission of The Association of Phy-
sicians from Chan et al. [30].  Oxford University Press.
Use: the QTc interval should be measured manually on a
12-lead ECG from the beginning of the Q wave until the
end of the T wave in multiple leads (i.e. six leads including
limb and chest leads and median QT calculated). The QTc
interval is plotted on the nomogram against the heart rate
recorded on the ECG. If the point is above the line then
the QTc–heart rate is regarded as ‘‘at risk’’. ECG electro-
cardiogram, QTc corrected QT
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on the clinical situation, close attention to the
QTc and even Holter monitoring may be
required. Table 4 outlines the principles of
managing hypertension and QTc interval
prolongation.
The mechanisms of specific cardiovascular
AEs in patients with MTC may differ from other
tumor types and can limit therapeutic options
for other AEs or comorbidities. Factors that may
be associated with QTc prolongation include
baseline QTc interval, electrolyte levels, and the
use of concomitant drugs. It should also be
remembered that thyroid function disorders
can lead to QTc prolongation and, therefore,
need correction [31]. Diarrhea may affect
electrolyte balance, necessitating close
monitoring of serum potassium, magnesium,
and calcium, and this may play a role in the
higher incidence of high-grade QTc interval
prolongation with vandetanib in thyroid versus
other tumor types. Table 5 lists agents that are
contraindicated or not recommended for
coadministration with vandetanib; an updated
list of agents that prolong QTc and/or induce
Table 4 Management of cardiovascular adverse events related to vandetanib therapy
Adverse
event
Recommendations Notes
Hypertension [6, 11]
Before
treatment
Blood pressure should be recorded at baseline In clinical trials, treatment with vandetanib did not
worsen hypertension in patients who had required
antihypertension treatment at baseline
Blood pressure should be stabilized according to
standard medical practice
During
treatment
Blood pressure should be monitored and controlled as
appropriate
Treatment may be resumed once hypertension is
appropriately controlled
If high blood pressure cannot be controlled with
medical management, vandetanib should not be
restarted until blood pressure is medically controlled
Reduction of vandetanib dose may be necessary
QTc prolongation [6, 11]
Before
treatment
An echocardiogram, ECG, and levels of serum
potassium, calcium, and magnesium and TSH
should be obtained at baseline
Vandetanib treatment must not be started in patients
with QTc[450 ms (US prescribing information
[5];[480 ms in EU summary of product
characteristics) [6]
Hypocalcemia, hypokalemia, and/or hypomagnesemia
must be corrected prior to vandetanib
administration
Vandetanib should not be given to patients with
congenital long QTc syndrome or a history of TdP
unless all risk factors that contributed to TdP have
been corrected
Vandetanib has not been studied in patients with
ventricular arrhythmias or recent myocardial
infarction
An annual echocardiogram may be useful for patients
at high cardiovascular risk (e.g. elderly with diabetes)
956 Adv Ther (2013) 30:945–966
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TdP may be found at the Arizona Center for
Education and Research on Therapeutics
(AZERT) CredibleMeds website [32]. QTc
prolongation is rarely a problem when
preventive measures are applied, including
avoidance of drugs known to prolong the QTc
interval, and when hypothyroidism,
hypokalemia, hypomagnesemia, and
hypocalcemia are corrected.
Management of Gastrointestinal AEs
Table 6 outlines the recommended treatment
and other management considerations for
gastrointestinal AEs, which include nausea,
vomiting, and diarrhea.
Substances used to manage chemotherapy-
induced nausea and vomiting include 5-HT3
receptor antagonists (also known as setrons),
dopamine D2 antagonists, and steroids
(dexamethasone 8 mg twice daily).
In general, 5-HT3 antagonists are associated
with the potential to increase the QTc interval.
The use of ondansetron should be avoided in
patients being treated with vandetanib,
particularly those who have cardiovascular
disease and a high risk of drug-induced TdP as
well. When used in patients with cardiovascular
Table 4 continued
Adverse
event
Recommendations Notes
During
treatment
An ECG, and levels of serum potassium, calcium, and
magnesium and TSH should be obtained at 1, 3, 6,
and 12 weeks after starting treatment and every
3 months for at least a year thereafter
Serum TSH, serum potassium, serum magnesium,
and serum calcium should be kept within normal
range
This schedule should apply to the period after dose
reduction due to QTc prolongation and after dose
interruption for more than 2 weeks
Coadministration of substances known to prolong
QTc is contraindicated or not recommended; in
particular, the concomitant use of vandetanib with
ondansetron is not recommended
ECGs and blood tests should also be obtained as
clinically indicated during this period and afterwards,
with frequent monitoring of the QTc interval
If antiemetic therapy is required, consider
palonosetron-based treatment
Additional monitoring of QTc, electrolytes, and renal
function is needed in case of diarrhea, increase in
diarrhea/dehydration, electrolyte imbalance, and/or
impaired renal function
If QTc increases markedly but stays below 500 ms,
cardiologist advice should be sought
Discontinue vandetanib in patients who develop a
single value of a QTc interval C500 ms
Dosing can be resumed at a reduced dose after
return of the QTc interval to pretreatment status
has been conﬁrmed and any possible electrolyte
imbalance has been corrected
ECG electrocardiogram, QTc corrected QT interval, TdP Torsades de Pointes, TSH thyroid stimulating hormone
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disease with one or more risk factors for TdP,
ondansetron increased the QTc interval by
about 19 ms for up to 120 min after
administration [33]. Palonosetron represents a
new generation of setrons and possesses the
highest affinity for the 5-HT3 receptor in this
class with the longest half-life of*40 h [34, 35].
In two small studies of patients receiving
chemotherapy, palonosetron did not cause
severe rhythmic disorders or symptomatic
electrocardiogram (ECG) changes [36], or a
statistically significant increase in median QT
minimum value [37]. Palonosetron may,
therefore, be considered an alternative
antiemetic therapy. Nevertheless, caution
should be exercised in its concomitant use
with medicinal products that increase the QTc
interval or in patients who have or are likely to
develop prolongation of the QT interval. As
palonosetron may increase large bowel transit
time, patients with chemotherapy-induced
diarrhea could benefit from this substance [34].
The antiemetic action of metoclopramide is
based on its D2 receptor antagonist activity.
However, at higher doses the substance also
exerts 5-HT3 antagonist activity. Thus,
metoclopramide may be associated with QTc
prolongation and should be used with caution
only [38].
Aprepitant is a neurokinin 1 (NK1) receptor
antagonist that is available for chemotherapy-
induced nausea and vomiting [39]. Signals
indicating QT-prolonging properties could not
be derived so far from 15 pharmacologic studies
[40].
Diarrhea, either due to the disease or
treatment, can impair quality of life in
patients with MTC, resulting in dose
reduction, interruption, or discontinuation of
therapy. It may also put patients at risk of
dehydration with electrolyte disturbance and
other potentially life-threatening complications
due to the QTc prolongation associated with
vandetanib. Diarrhea frequently worsens during
antibiotic therapy that may be given for
folliculitis.
Diarrhea may also exist in MTC because of
the production of hormones that accelerate
gastrointestinal motility and may improve
with vandetanib treatment. In addition, the
use of agents that slow peristaltic movements
(e.g. loperamide) or mild opioids (e.g. codeine)
can provide relief that is usually partial.
Evidence on the efficacy of somatostatin
analogs against diarrhea in patients with MTC
is not available.
As with other types of AEs, awareness and
education regarding GI tolerability is a key part
of patient education. Typical measures to take
when confronted with diarrhea are listed in
Table 2. QTc prolongation can also occur with
hypokalemia; therefore, regular monitoring of
serum electrolytes is essential. In case of severe
GI symptoms, vandetanib should be stopped
Table 5 Selection of agents that are contraindicated or
not recommended for coadministration with vandetanib
Contraindicated Not recommended
Arsenic Amisulpride
Cisapride Chlorpromazine
Class IA and III antiarrhythmics Halofantrine
Intravenous erythromycin Haloperidol
Mizolastine Lumefantrine
Moxiﬂoxacin Methadone
Toremifene Metoclopramide
Ondansetron
Pentamidine
Sulpiride
Zuclopenthixol
As recommended in the vandetanib summary of
characteristics [6]
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until symptoms improve. In severe diarrhea
persisting after cessations of treatments, a stool
work-up should be performed to exclude
organic causes.
Management of Generalized AEs
The effect of generalized AEs on quality of life
can vary. While many patients are able to
maintain normal activity schedules, others
experience debilitating fatigue that leads to
dose limitation or treatment discontinuation
[13]. Fatigue comprises emotional, physical,
and/or cognitive tiredness and can be a
distressing and persistent AE. It is usually
multifactorial and may arise as a symptom of
the underlying burden of disease,
hypothyroidism, anemia, depression, sleep
disturbances, or pain, and can thus be difficult
to address. Management of fatigue is primarily
supportive; however, it is important to identify
treatable causes contributing to it. Patients
should be assessed for depression and
appropriate treatment measures (avoiding drugs
that may prolong QTc) should be introduced to
optimize emotional and social support.
Vandetanib treatment in patients with MTC
increases visceral fat and muscle body content,
in contrast to other TKIs [41]. This positive
effect should be taken into consideration and
patients on vandetanib should be encouraged to
follow a normal social and professional life, and
participate in sports activities. It is worth noting
that pregnancy constitutes a contraindication
for vandetanib therapy and effective
contraception is necessary for all patients.
Other AEs reported with vandetanib therapy
include reversible posterior leukoencephalopathy
syndrome, which requires treatment withdrawal,
and cornea verticillata, which is responsible
for blue vision and regresses with dose reduction
[5].
Nursing Care for Patients Receiving
Vandetanib for MTC
As an integral part of a multidisciplinary care
team, an experienced specialist nurse is in a
unique position to facilitate early detection,
intervention, and coordinated management of
AEs arising with vandetanib treatment. As a
number of AEs are typically seen in the first
3 months of vandetanib treatment, close
patient contact is important during this
period. Clinic visits may be scheduled every
2 weeks for the first 6–8 weeks to accommodate
ECG, serum electrolyte monitoring, and review
of emerging AEs.
Apart from providing vital patient education
(Table 2), specialist nurses are typically faced
with the challenges of eliciting AE information
from patients. While some patients may feel
more comfortable discussing AEs with a nurse
rather than a physician, not all patients realize
the importance of reporting specific symptoms
and they may not contact the clinic if they
experience AEs during treatment. Therefore, it
is important that patients are made aware, often
by the specialist nurse, of symptoms to look out
for and the value of reporting at an early stage.
A list of drugs that should be avoided during
vandetanib treatment should be given to the
patient so that any care provider can check
whether a drug can be safely given or not and,
in case of doubt, contact a specialist nurse or
physician. In addition, patients must be made
aware of the importance of informing their
specialist nurse and/or physician of any
concomitant medication started by other
clinicians for comorbidities. These should be
carefully documented and cross-checked to
avoid possible dangerous drug interactions.
Oncology nurses also have to deal with the
logistical impact of geographical distance on
patient visits. With the rarity of MTC, it is not
Adv Ther (2013) 30:945–966 961
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unusual for patients to live far away from
tertiary care specialist clinics. This may
necessitate contact via telephone as a
replacement for a clinic visit. If required, a
visit from an experienced oncology nurse can be
substituted for a doctor’s appointment.
Alternative options to ensure open patient
communication (e.g. a telephone dedicated by
the clinic as a helpline, internet video calls, call
center) may be considered, subject to the
clinic’s policies and resources. Through
effective use of clinical knowledge, patient
Table 7 Pocket guidelines for the management of adverse events with vandetanib
Adverse
event
Patient education before starting treatment At the time adverse event emerges
Skin toxicity Prophylactic use of hydrating creams all over the
body, especially areas of sun-exposed skin and
hands and feet
Early use of fatty ointments and urea creams. If no
improvement, the addition of topical steroids, with
or without antibiotics, could be helpful. The oral
administration of cloxacillin and anti-histamines also
may help
Diarrhea Patient education with dietary measures As soon as diarrhea is apparent, oral hydration and
anti-diarrhea medications such as loperamide 2 mg,
taken after every fecal deposit up to a maximum of
16 mg per day, is required. Special care should be
taken with elderly patients who have a higher risk of
dehydration
Nausea and
vomiting
Patient education with dietary measures Common antiemetics such as metoclopramide or
ondansetron are not recommended to prevent or
relieve vomiting and nausea. There is a need to ensure
correct hydration
Fatigue and
asthenia
Treat underlying factors according to standard
medical practice that may induce or promote
fatigue
Monitor for possible comorbidities that could
contribute to fatigue
Advise patients to maintain a healthy diet and to
take moderate exercise
Mucositis
and/or
stomatitis
Recommend patients to switch to a mild
toothpaste and a soft toothbrush
Rinse mouth with water and use alcohol-free
mouthwash
Use lip creams or balms
Avoid alcohol, acidic food and drink, and excessively
hot (temperature) food
Hypertension Blood pressure should be checked and controlled
appropriately
Prescribe anti-hypertensive medication such as ACE
inhibitors
Educate patients to measure blood pressure and to
recognize the most common symptoms of
hypertension
ACE angiotensin-converting-enzyme
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assessment, and advocacy skills, nurses play a
key role in the care of patients with MTC.
SUMMARY AND CONCLUSION
Vandetanib has recently demonstrated clinical
benefit in patients with MTC [7]. Other
promising agents are in clinical development,
and sequencing strategies are likely to expand
treatment options and translate to improved
survival outcomes in the near future. Patients
will potentially receive vandetanib in addition
to supportive treatment for comorbidities over a
period of several months or years, presenting a
unique situation compared with the
management of other solid tumor types. With
the prospect of longer life expectancy, quality of
life is likely to be a determining factor for
treatment compliance.
This review proposes pragmatic guidelines
for management of AEs related to vandetanib
therapy for MTC. For those community
physicians who may only treat one or two of
these patients per year, we suggest following the
‘‘Pocket guidelines for management of
vandetanib adverse events’’ reflected in Table 7.
As with many other targeted cancer
therapies, vandetanib is associated with a
number of AEs; however, these are generally
mild and readily manageable. Informed consent
and education about potential treatment-
related AEs will help patients anticipate and
recognize any tolerability issues with the drug,
and active monitoring will allow for early
detection and control of AEs that arise. A
multidisciplinary approach is strongly
recommended, with close coordination and
care of patients and their individual needs.
These patients have complex requirements and
should be treated holistically. The
multidisciplinary team, therefore, plays a
critical role in providing optimal AE
management and patient support to optimize
treatment outcomes in this setting.
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